Tolerability, pharmacokinetics, and anti-herpetic activity of orally administered BX795.

[1]  C. Patil,et al.  Intrinsic Antiviral Activity of Optineurin Prevents Hyperproliferation of a Primary Herpes Simplex Virus Type 2 Infection. , 2021, Journal of immunology.

[2]  S. Mallick,et al.  BX795-Organic Acid Coevaporates: Evaluation of Solid-State Characteristics, In Vitro Cytocompatibility and In Vitro Activity against HSV-1 and HSV-2 , 2021, Pharmaceutics.

[3]  Tejabhiram Yadavalli,et al.  Porcine Corneal Tissue Explant to Study the Efficacy of Herpes Simplex Virus-1 Antivirals. , 2021, Journal of visualized experiments : JoVE.

[4]  Tejabhiram Yadavalli,et al.  Prophylactic treatment with BX795 blocks activation of AKT and its downstream targets to protect vaginal keratinocytes and vaginal epithelium from HSV-2 infection. , 2021, Antiviral research.

[5]  Joshua M Ames,et al.  Standalone or combinatorial phenylbutyrate therapy shows excellent antiviral activity and mimics CREB3 silencing , 2020, Science Advances.

[6]  Vineet D. Menachery,et al.  Evasion of Type I Interferon by SARS-CoV-2 , 2020, Cell Reports.

[7]  R. Koganti,et al.  In Vitro and In Vivo Activity, Tolerability, and Mechanism of Action of BX795 as an Antiviral against Herpes Simplex Virus 2 Genital Infection , 2020, Antimicrobial Agents and Chemotherapy.

[8]  Joshua M Ames,et al.  Prior inhibition of AKT phosphorylation by BX795 can define a safer strategy to prevent herpes simplex virus-1 infection of the eye. , 2019, The ocular surface.

[9]  Daniel Epling,et al.  Evaluating the intestinal and oral absorption of the prodrug valacyclovir in wildtype and huPepT1 transgenic mice , 2018, Biochemical pharmacology.

[10]  G. van Loo,et al.  Optineurin Functions for Optimal Immunity , 2018, Front. Immunol..

[11]  Abraam M. Yakoub,et al.  An off-target effect of BX795 blocks herpes simplex virus type 1 infection of the eye , 2018, Science Translational Medicine.

[12]  J. Ashwell,et al.  The TBK1‐binding domain of optineurin promotes type I interferon responses , 2016, FEBS letters.

[13]  Yoshiaki Ohtsu,et al.  Pharmacokinetics and Pharmacodynamics of ASP2151, a Helicase-Primase Inhibitor, in a Murine Model of Herpes Simplex Virus Infection , 2012, Antimicrobial Agents and Chemotherapy.

[14]  L. Morrison,et al.  Genome Sequence of Herpes Simplex Virus 1 Strain McKrae , 2012, Journal of Virology.

[15]  P. Cohen,et al.  Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream kinase mediates Ser-172 phosphorylation and activation. , 2009, The Journal of biological chemistry.

[16]  D. Goldblum,et al.  Comparison of oral antiviral therapy with valacyclovir or acyclovir after penetrating keratoplasty for herpetic keratitis , 2008, British Journal of Ophthalmology.

[17]  T. Foster,et al.  Ocular HSV-1 Latency, Reactivation and Recurrent Disease , 2008, Seminars in ophthalmology.

[18]  T. L. Keadle,et al.  Ocular herpes simplex: changing epidemiology, emerging disease patterns, and the potential of vaccine prevention and therapy. , 2006, American journal of ophthalmology.

[19]  L. Stanberry,et al.  Is herpes simplex virus type 1 (HSV-1) now more common than HSV-2 in first episodes of genital herpes? , 2003, Sexually transmitted diseases.

[20]  W. Snowden,et al.  Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir. , 2002, Journal of Infectious Diseases.

[21]  T. Liesegang.  Herpes Simplex Virus Epidemiology and Ocular Importance , 2001, Cornea.

[22]  K. Beutner,et al.  Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. , 1995, Antiviral research.

[23]  R. Elton,et al.  The epidemiology of herpes simplex types 1 and 2 infection of the genital tract in Edinburgh 1978-1991. , 1993, Genitourinary medicine.

[24]  C. Foster,et al.  Antiviral medications and corneal wound healing. , 1984, Antiviral research.

[25]  K. Holmes,et al.  Genital herpes simplex virus infections: clinical manifestations, course, and complications. , 1983, Annals of internal medicine.

[26]  R. N. Brogden,et al.  Trifluridine: A Review of its Antiviral Activity and Therapeutic Use in the Topical Treatment of Viral Eye Infections , 1982, Drugs.